PDA

View Full Version : IsoRay completes Cs-131 brachytherapy seeds feasibility study for breast cancer treat


News
10-28-2010, 04:09 AM
IsoRay, Inc. announced, today, it has completed an initial feasibility study, which demonstrates the ability to use its patented Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) in accelerated partial breast irradiation (APBI) for breast cancer treatment.

More... (http://www.news-medical.net/news/20101028/IsoRay-completes-Cs-131-brachytherapy-seeds-feasibility-study-for-breast-cancer-treatment.aspx)